Clostridium difficile vaccines composed of surface polysaccharides (PSs) have the potential to simultaneously control infection and colonization levels in humans. C. difficile vaccines based on PS-II have attracted the most attention due its facile purification and ubiquitous expression by C. difficile ribotypes. Anti PS-II antibodies recognize both C. difficile vegetative cell and sporulating preparations and confer protection against C. difficile infection. https://doi.org/10.1007/978-1-4939-3387-7_21
Carbohydrate chemist Mario Monteiro develops vaccines to thwart pathogenic bacteria. His latest challenge may be his biggest yet — creating a vaccine to fight the gastric bugs that cause havoc in the lives of autistic children.
"In the C. difficile vaccine arena, Matrivax has demonstrated in two distinct preclinical animal models that a vaccine candidate containing both protein and polysaccharide antigens provided superior protection compared to each antigen separately. Development of scalable purification processes for protein and polysaccharide antigens is in progress and GMP production is scheduled to begin in 2018."
He never quite leaves the chemistry lab behind. Even as he heads home each day, part of Prof. Mario Monteiro remains in U of G’s MacNaughton Building with his studies of carbohydrate-based vaccines. And that part of him is still there the next morning. “I do wake up thinking about the research,” he says. “It’s not like I close the door.”
Recipient of the University of Guelph Inaugural Innovation Award
[Said University of Guelph vice-president research Malcolm Campbell]
“Prof. Monteiro’s research led to the world’s first vaccine that may be capable of controlling both infection and colonization levels from C. difficile."
The challenges of taking lab concepts to commercialization were the focus of a Talk Local Guelph interview April 4. Chemistry professor Monteiro, and technology transfer manager David Hobson (P. Eng. DVSc.) explained the complicated path to take an idea to market...
A vaccine invented at the University of Guelph to protect against Campylobacter jejuni – one of the leading bacterial causes of food-borne illness in the world – has just been approved for human clinical trials by the United States Food and Drug Administration (FDA). It’s the first U of G technology to reach this testing phase. “It’s very rare that you have a discovery go this far,” said chemistry professor Mario Monteiro.
The tuberculosis (TB) vaccine hasn’t changed much since it was first used on humans almost a century ago, yet the disease is still prevalent in Canada’s aboriginal communities and in developing countries.
“It’s not effective anymore, especially in adults,” says University of Guelph chemistry professor Mario Monteiro. “It’s not even used now in North America.”
Monteiro is working on a new — and hopefully more effective — type of TB vaccine that uses a plant-based ingredient to trigger an immune response in the body.
Dr. Silvia Borrelli presents our research at the European Carbohydrate Symposium
Dr. Silvia Borrelli presents our most advanced vaccine research at the 19th European Carbohydrate Symposium in Spain. Silvia will describe our vaccines against the gastric pathogens Clostridium difficile and Campylobacter jejuni.